| INTRODUCTION
The term pituicytoma was first introduced by Liss 3 Immunohistochemical analysis shows a general positivity for glial fibrillary acidic protein (GFAP), thyroid transcription factor 1 (TTF1), 5, 6 and S100, 3 as well as an occasional positivity for vimentin. 7 Recently positivity for vascular endothelial growth factor (VEGF) has been described. 7 With the revision of the World Health Organization Classification of Tumors in 2016, these entities are classified as group I of TTF1-expressing tumors, 8 a group also containing spindle cell oncocytoma and granular cell tumor who were historically already discussed to be the same tumor family as pituicytoma.
9
So far, only 96 cases have been published [10] [11] [12] with the largest series containing 11 patients 12 while most descriptions are single case reports or small series of no more than three tumors. Surgery with complete tumor resection is a curative option and therefore considered the primary goal of any treatment. However, due to a tendency toward strong vascularization and adherence to the surrounding tissue, the goal of gross total resection (GTR) is not always reachable. In a recent review of 67 cases by Feng, only 42% of all transsphenoidal approaches and 33% of all craniotomies could reach GTR. 10 As resection often remains incomplete, recurrence can be observed in up to 30% after subtotal tumor removal. 10 After recurrence, either repeat surgery or radiotherapy has been tried for further treatment. Due to the high rates of recurrence, lesions suspicious of a pituicytoma should be treated only when symptomatic or when radiographic progression is seen in order to omit complications and keep the patient out of harm's way.
Targeted therapies as an alternative treatment method have not yet been described for recurrent pituicytoma but may be a possible treatment option after incomplete resection and radiotherapy.
Karamandchani et al. in their study from 2012 described a diffuse positivity for VEGF. 7 However, receptors for targeted therapies have to our knowledge not yet been described. In order to establish individual treatment algorithms in surgically difficult cases or recurring pituicytoma, the aim of this study was to assess the presence of the necessary receptor configuration for potential alternative therapies.
| METHODS
We identified nine patients with histologically confirmed pituicytoma ( 
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| RESULTS
Nine patients were surgically treated for pituicytoma; one was treated twice by one of the senior surgeons (once for recurrence). GTR was F I G U R E 1 T1-weighed biplanar MRI with contrast enhancement (Gadolinium). Left: Coronal view. Right: Sagittal view, both with suprasellar pituicytoma as a homogenously enhancing suprasellar mass achieved in three cases (33.3%), and no recurrence was observed for GTR. Six patients underwent only partial removal. Two-thirds (66.6%) of the tumors removed only in part showed excessive bleeding intraoperatively, three received adjuvant radiation therapy, and one of those showed a recurrent tumor. One patient with incomplete resection and remarkable intra-operative bleeding was treated with repeat surgery a year later due to tumor progression, and this patient died 3 weeks after surgery due to extensive postoperative hemorrhage at the site of resection (Figure 2 ).
Symptoms and endocrine dysfunction are presented in Table 1 ; initially, no patient showed deterioration of posterior pituitary function.
Only in one patient pituitary function improved after surgery, and the previously observed amenorrhea was completely reversible.
Routine microscopy of the tumors in our series showed the characteristic spindle cell pattern for all tumors with varying degree of storiform to diffuse growth patterns. Ki67 labeling index was low (<1%) in one of 10 cases, medium (1%-5%), 7 of 10 cases, and high (10%) in two cases. One high Ki67 of 10% was found in patient #8 also presenting recurrent pituicytoma. For the case #3, the Ki67 increased from initial surgery to repeat surgery (<1%-4.4%). There was a strong positivity for TTF1 in all samples, vimentin was available for 6 of 10 samples and always stained positive. GFAP expression was observed irregularly in 33% of all cases, whereas S100 was found positive in 90% (9 of 10 cases) both markers always stained with high intensity.
Synaptophysin was slightly positive in one case (1 of 6 cases) and otherwise negative.
| Potential target receptors
After staining, the ten samples of pituicytoma a uniform positivity for VEGF-R was observed in all tumor specimens, VEGF ligand was originally stained in four cases, and only one showed mild signs of staining ( Figure 3A ,B).
Somatostatin receptor (SSTR) 2 showed only slight positivity in three samples, and all others were negative. It stained slightly positive for patient #3 initially but was negative on recurrence.
A positivity for SSTR 3 was observed in six cases (three strong, three medium), one showed slight staining, and three were negative.
There was an increase in expression for the recurring tumor of patient #3.
SSTR 5 was positive in seven samples (six medium, one slightly) and negative in three samples (Table 2) .
Controls on healthy neurohypophyseal samples showed no expression of SSTR 2, 3, or 5. VEGF-R was present only within the capillary tissue of the posterior hypophysis and very few pituicytes.
| DISCUSSION
In the present study, we analyzed 10 pituicytoma samples of nine patients in order to investigate the presence of receptors for targeted therapies. All tumors showed a strong positivity for VEGF-R and 67%
were 14 Additionally, in a recent larger study comparable adverse event ratios for standard treatment and additional bevacizumab in human glioblastoma were shown. 15 Therefore, bevacizumab may still be a viable therapeutic option after failed resection and radiation therapy.
The somatostatin receptors may also be available for a direct antitumoral treatment regime using somatostatin analogues; however, we found a strong variation in tumor receptor expression. As the samples from our collective were all mechanically stained in one batch, a technical inaccuracy is very unlikely. Therefore, we conclude that SSTR receptor expression seems to be of some variance within the tumor collective of pituicytoma. The receptor may still me a ligand for a targeted therapy, but specific qualitative and quantitative examinations should precede the decision on such a treatment.
Two methodologically different treatment alternatives exist in this sector. Somatostatin receptor analogues are ligands to the receptor inducing cell cycle arrest and a downregulation of protein biosynthesis therefore creating an imbalance toward increased apoptosis within the affected stroma. 16, 17 Also as a secondary effect, somatostatin analogues, like VEGF inhibitors, also affect tumor vascularization; this may be of special importance due to the highly vascular nature of the pituicytoma itself. 17 As pituicytoma samples in our study stained mainly for SSTR 3 and 5, the use of, for example, pasireotide with a high affinity to those receptors may be a potential option. 17 This agent has so far been approved for the use as a second line treatment in Cushing's disease and acromegaly and shown good clinical results including tumor mass reduction, 18, 19 An alternative tumor treatment method also employing the somatostatin receptor as a target structure may be the use of radiolabeled T A B L E 2 Receptor configuration for target therapies: Degree of positivity 0/+/++/+++; n.a.=stain not available. somatostatin analogues like DOTATOC or DOTATATE. 20, 21 The key principle of this approach is the accumulation of local toxicity through beta radiation of isotopes attached to somatostatin receptor ligands.
21
The main target receptor in the approaches for the central nervous system so far has been SSTR 2 20 because of the high affinity of the available radiotracers toward this structure. 22 This is unfortunate for the case of pituicytoma which showed no particular expression of SSTR 2 in our series; the available ligands do, however, bind to SSTR 3 and 5 as well but with lower affinity. 22 A therapeutic approach may therefore still be possible, but radiotracers with high affinity for SSTR 3 and 5 and a low affinity for SSTR 2 are necessary; otherwise undesired higher toxicity and adverse effects in other nontumor tissue may result; however these results may be employed in a diagnostic approach prior to surgery, for example, by DOTATOC-PET.
Regarding tumor diagnostics, we could confirm the findings by previous studies describing multiple pituicytoma histologies. 2, 11, 12, 23 Typically, the tumors presented spindle cell architecture with a storiform or interlacing pattern 11 and only few mitoses. The Ki67 labeling index showed a stronger variation (1%-10%) compared to the literature where it has been reported at 1%-6%, 12,24 especially in our cases of recurring pituicytoma the Ki67 labeling index appeared to be increased. In the case of recurrent pituicytoma with present first and second histology, we could observe an increase of the Ki67 from <1%-4.4% potentially explaining the sudden clinically apparent tumor growth. However, one patient with 10% Ki67 did not show recurrence probably due to complete resection. Another case with 5% Ki67 was partly resected but received immediate postoperative radiation therapy and may therefore not have shown recurrent growth. Aside from ultrastructural features, we could confirm the regular presence of S100 except for a single case that did not stain accordingly and were able to observe the reported positivity of TTF1 and vimentin 12 in all of our samples. GFAP expression was variable and only present in 33% of our cases and synaptophysin only stained positive in one sample also confirming previous investigations.
11,12,24
| CONCLUSION
Pituicytoma of the neurohypophysis is a rare but usually benign neoplasia of the central nervous system, which may pose a challenging therapy, due to the difficulty resulting from strong adherence, invasion, and bleeding tendency. As the majority of tumors are not completely resectable and recurrence after partial removal is high, adjuvant therapies move into the therapeutic focus. Targeted therapies may be a possible option in this treatment regime in the future, especially the strong representation of VEGF-R may be an excellent target for individual treatment approaches. A more practical approach may be SSTR-based treatments considering the variable SSTR receptor expression as serious adverse events may be reduced.
